Marie Curie Palliative Care Research Department, UCL, London, UK.
Palliat Med. 2019 Jun;33(6):578-588. doi: 10.1177/0269216319826007. Epub 2019 Feb 12.
Little research has explored the detail of practice when using sedative medications at the end of life. One work package of the I-CAN-CARE research programme investigates this in UK palliative care.
To investigate current practices when using sedative medication at the end of life in London, UK, by (1) qualitatively exploring the understandings of palliative care clinicians, (2) examining documented sedative use in patient records and (3) comparing findings from both investigations.
We conducted focus groups with experienced palliative care physicians and nurses, and simultaneously reviewed deceased patient records.
SETTING/PARTICIPANTS: In total, 10 physicians and 17 senior nurses in London hospice or hospital/community palliative care took part in eight focus groups. Simultaneously, 50 patient records for people who received continuous sedation at end of life in the hospice and hospital were retrieved and reviewed.
Focus group participants all said that they used sedative medication chiefly for managing agitation or distress; selecting drugs and dosages as appropriate for patients' individual needs; and aiming to use the lowest possible dosages for patients to be 'comfortable', 'calm' or 'relaxed'. None used structured observational tools to assess sedative effects, strongly preferring clinical observation and judgement. The patient records' review corroborated these qualitative findings, with the median continuous dose of midazolam administered being 10 mg/24 h (range: 0.4-69.5 mg/24 h).
Clinical practice in these London settings broadly aligns with the European Association for Palliative Care framework for using sedation at the end of life, but lacks any objective monitoring of depth of sedation. Our follow-on study explores the utility and feasibility of objectively monitoring sedation in practice.
很少有研究探讨在生命末期使用镇静药物时的具体实践。I-CAN-CARE 研究计划的一个工作包在英国姑息治疗中对此进行了调查。
通过(1)深入探讨姑息治疗临床医生的理解,(2)检查患者记录中记录的镇静药物使用情况,(3)比较这两种调查结果,来研究在英国伦敦生命末期使用镇静药物的当前实践。
我们进行了有经验的姑息治疗医生和护士的焦点小组讨论,同时审查了已故患者的记录。
地点/参与者:共有 10 名医生和 17 名伦敦临终关怀医院或医院/社区姑息治疗的高级护士参加了 8 个焦点小组。同时,检索并审查了在临终关怀和医院接受持续镇静治疗的 50 名患者的记录。
焦点小组的参与者都表示,他们主要使用镇静药物来管理躁动或痛苦;根据患者的个体需求选择适当的药物和剂量;并尽可能使用最低剂量使患者“舒适”、“平静”或“放松”。没有人使用结构化的观察工具来评估镇静效果,而是强烈倾向于临床观察和判断。患者记录的审查证实了这些定性发现,中位数持续咪达唑仑剂量为 10mg/24h(范围:0.4-69.5mg/24h)。
这些伦敦环境中的临床实践与欧洲姑息治疗协会在生命末期使用镇静药物的框架基本一致,但缺乏对镇静深度的任何客观监测。我们的后续研究探讨了在实践中客观监测镇静的效用和可行性。